Company profile
MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sonelokimab | phase3 | — | 10 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06411899 | phase3 | completed | 2024-05-15 | 2025-09-02 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT07007637 | phase3 | enrolling_by_invitation | 2025-06-27 | 2028-06-13 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT07223138 | phase3 | enrolling_by_invitation | 2025-11-13 | 2028-02-04 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis |
| NCT06994936 | phase1 | completed | 2025-06-05 | 2025-11-01 | MoonLake Immunotherapeutics AG | An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector |
| NCT06768671 | phase3 | active_not_recruiting | 2024-12-30 | 2026-09-28 | MoonLake Immunotherapeutics AG | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) |
FDA applications (0)
No records yet.